Clinical Report: IDSA updates guidance for antimicrobial-resistant gram-negative infections

Overview

The Infectious Diseases Society of America has released updated guidance for treating antimicrobial-resistant gram-negative infections, emphasizing newer therapies and evidence-based recommendations. This guidance addresses six major pathogen groups and is applicable to both adults and children.

Background

Antimicrobial resistance is a significant public health concern, particularly with gram-negative infections that are increasingly difficult to treat. The updated guidance reflects the latest evidence and expert consensus.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• The guidance covers six resistant gram-negative pathogen groups: ESBL-E, AmpC-E, CRE, DTR P. aeruginosa, CRAB, and S. maltophilia.
• Carbapenems are preferred for invasive ESBL-E infections outside the urinary tract, with specific recommendations for critically ill patients.
• For AmpC-E infections, cefepime is preferred when the organism is susceptible, while ceftriaxone is generally avoided.
• CRE treatment varies by resistance mechanism, with specific agents recommended for KPC and MBL-producing infections.
• New beta-lactam agents may retain activity against DTR P. aeruginosa, and susceptibility testing is recommended for these agents.
• Cefiderocol monotherapy is preferred for invasive S. maltophilia infections, although based on animal-model data.

Clinical Implications

Utilize susceptibility testing to guide antibiotic selection and consider patient-specific factors such as safety and tolerability. Distinguishing between true infections and colonization is important to optimize antibiotic use.

Conclusion

The updated IDSA guidance provides a comprehensive framework for managing antimicrobial-resistant gram-negative infections, reflecting current evidence and expert consensus.

Related Resources & Content

1. Infectious Diseases Society of America, Clinical Infectious Diseases, 2026 -- IDSA updates guidance for antimicrobial-resistant gram-negative infections
2. MDSpire News — Antibiotic Guideline Gaps Raise SSI Risk
3. Infection — Guidelines from the German Society for Infectious Diseases on Promoting Rational Antibiotic Use in Hospitals
4. Open Forum Infectious Diseases — Assessment of Aminoglycoside Dosing Strategies Tailored to Renal Function and Updated Interpretive Criteria for Enterobacterales and Pseudomonas aeruginosa: A Concise Overview
5. ada news — New CDC resources address antibiotic stewardship
6. Antibiotic Guideline Gaps Raise SSI Risk
7. Guidelines from the German Society for Infectious Diseases on Promoting Rational Antibiotic Use in Hospitals
8. Assessment of Aminoglycoside Dosing Strategies Tailored to Renal Function
9. New CDC resources address antibiotic stewardship
10. IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
11. These highlights do not include all the information needed to use EMBLAVEO ® safely and effectively. See full prescribing information for EMBLAVEO .       EMBLAVEO ( aztreonam and avibactam ) for injection, for intravenous use   Initial U.S. Approval: 20 25
12. Drug Trials Snapshots: EXBLIFEP | FDA
13. CONTEPO (fosfomycin) for injection, for intravenous use
14. IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
15. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis - PMC